Skip to Main Content

Updated with Vertex comment.

Vertex Pharmaceuticals (VRTX) terminated a small clinical trial involving an important, long-acting version of its cystic fibrosis drug Kalydeco that was acquired from Concert Pharmaceuticals (CNCE) earlier this summer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!